On the morning of June 4, 2019, He Ping, Deputy Mayor of Deyang Municipal People's Government and other leaders visited China Health Union Biomedical Technology (Sichuan) Co., Ltd. for investigation and Gao Zhonghua, Chairman of China Health Union Biomedical Technology (Sichuan) Co., Ltd. , Yang Xuping, Executive General Manager of Sichuan Junteng Cell Gene Technology Development and Application Co., Ltd., Nie Xiaoning, Deputy General Manager of Sichuan Gaorunde Biotechnology Co., Ltd., and other company leaders accompanied the investigation. Hu Ruiyang, deputy director of the Municipal Government Office, and deputy director of the Municipal Health Commission Kang Min and other leaders.
1589802588163303.jpg
The deputy mayor of the municipal government, He Ping, and other leaders visited the Sichuan Province Human Cell and Gene Biological Sample Bank, Cell Preparation and Storage Center, Quality Testing Center, precision medicine and third-party clinical medical testing and molecular biology laboratories, and humanized therapeutics. Key laboratories such as antibody first-class new drug industrialization screening platform, new drug innovation research and development and new drug evaluation center. He Ping, the deputy mayor of the municipal government, has a comprehensive understanding of our company’s development history, business model, corporate culture, talent reserve, stem cell storage, application, treatment, product research and development, and development, and gave the company’s project laboratory construction Fully affirmed.
At the symposium, the company’s chairman Gao Zhonghua first expressed his deep gratitude to Vice Mayor He Ping and other leaders who have cared about and supported the company’s development for a long time. He also welcomed the visit of Deputy Mayor He Ping and other leaders and expressed his appreciation for the company’s development. Deputy Mayor Ping and other leaders gave a detailed report: After 13 months, the "Human Cell and Biological Sample Bank", "Humanized Antibody Drug Screening Platform", "New Drug Innovation and Development and New Drug Verification Service Platform" have been fully established. Precision Medicine and Third-Party Clinical Testing Center” was awarded the “Deyang Key Laboratory of Stem Cells and Genes” issued by the Deyang Municipal People’s Government in 2018. Now all four platforms have passed the GMP laboratory testing of the Deyang Food and Drug Safety Inspection Center.
In terms of the stem cell industry: The first standardized and well-arranged immune cell evaluation and stem cell storage bank (stem cell preparation center, immune cell preparation storage center, gene screening storage center, cell and gene technology research and development center, cell and gene Technology Application Promotion Center), with the storage capacity of 1 million tubes of stem cells, which can carry out storage, application and treatment of umbilical cord mesenchymal stem cells, placental decidual stem cells, placental hematopoietic stem cells, deciduous tooth stem cells, adipose stem cells, immune cells, and regenerative medicine Research and development and clinical transformation, cellular medical beauty anti-aging and genetic screening and diagnosis services.
In terms of new drug research and development: The current product under research is: S1680 is a large molecule innovative drug research and development for multiple lipid metabolism diseases including rare diseases. It has been funded by angel round financing of 10 million and a round of financing of 35 million. Now, with a total of 125 million capital support of 80 million in round B financing, it has successfully developed an innovative drug for rare diseases of abnormal lipid metabolism. At present, the project has entered the clinical trial application stage and is expected to receive clinical approval in 2020.
